CeloNova BioSciences has provided details of its activities at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October—2 November, Washington, DC, USA). A press release reports that preliminary clinical data, including primary endpoint, from the COBRA PzF NanoCoated coronary stent development programme will be presented. Additionally, pre-clinical data comparing tissue response characteristics of the COBRA PzF NanoCoated Coronary Stent to leading polymer-based drug eluting stents will be presented in a poster session.
According to the press release, the COBRA PzF stent combines a cobalt chromium platform design with a biocompatible Polyzene-F nano-thin polymer. It is the first nanocoated stent to ever be evaluated in clinical trials in the USA. The following COBRA PzF presentations will take place at TCT 2016:
Session 1: Metallic platforms with durable permanent polymers. Presentation: Can passive coatings make a difference: Results with the COBRA PzF nanocoated coronary stent; 31 October, 8am–8.51am (actual presentation: 8.22am–8.29am)
Session 2: Rethink DAPT: Optimizing PCI in high-bleeding risk patients with the COBRA PzF NanoCoated Stent (NCS)—sponsored; 1 November 11.30am—12.30pm
Poster presentation: Abstract 2589: Endothelial Cell Coverage and Inflammation Comparing COBRA Polyzene-F (PzF) Coated Stent to Durable Fluoropolymer and Biodegradable Polymer Drug-Eluting Stents in a Rabbit Model; 29 October, 6–8pm
Dennert Ware, interim chief executive officer and executive chairman of the board of CeloNova, says: “The unveiling of our preliminary data findings from our novel Polyzene-F core clinical development programme represents a significant milestone as we work to transform the treatment of cardiovascular disease. Our currently enrolling COBRA REDUCE trial is evaluating the potential to reduce the need for long-term dual antiplatelet therapy for patients who are at high-risk for bleeding but require treatment for coronary disease.”